Samsung Bioepis Doubles Profits After European Ustekinumab Debut
Sales Up By More Than Half In 2024 As Major US Launches Planned For H1
Samsung Bioepis has reported a major boost to its operating results in 2024, lifted by biosimilar launches that included its Pyzchiva rival to Stelara in Europe through partner Sandoz, which the firm says has gained the largest market share among ustekinumab challengers.
